Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer DOI Creative Commons

Xiaobin Cao,

Jing Li,

Siyu Liu

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 11, 2025

Background Early diagnosis of lung cancer is crucial for improving patient outcomes. Autoantibodies against tumor-associated antigens (TAAs) found in the plasma can serve as biomarkers detection. Copper transporter 1 (COPT1) abnormally expressed several cancers including cancer. The purpose this study to explore significance anti-COPT1 autoantibodies clinical non-small cell (NSCLC). Methods expression level COPT1 NSCLC and normal tissues was analyzed based on TCGA Human Protein Atlas (HPA) database. Through enzyme-linked immunosorbent assay (ELISA), levels samples from controls (NC), patients with benign pulmonary nodules (BPN), were detected discovery (89 NC 89 NSCLC) verification (321 NC, 321 BPN groups. ELISA results verified by western blotting indirect immunofluorescence experiments. Results Based HPA databases, mRNA protein higher than tissues. anti-COPT1-IgG anti-COPT1-IgM significantly ( P <0.05). Anti-COPT1-IgG could discriminate area under curve (AUC) values 0.733 (95% CI: 0.694-0.771) 0.679 0.638-0.720), respectively. Additionally, combination anti-COPT1-IgG, anti-COPT1-IgM, carcinoembryonic antigen (CEA) enhance efficacy increased AUC values. Conclusions Our indicated potential novel detection NSCLC. Furthermore, improved diagnostic value.

Язык: Английский

Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer DOI Creative Commons

Xiaobin Cao,

Jing Li,

Siyu Liu

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 11, 2025

Background Early diagnosis of lung cancer is crucial for improving patient outcomes. Autoantibodies against tumor-associated antigens (TAAs) found in the plasma can serve as biomarkers detection. Copper transporter 1 (COPT1) abnormally expressed several cancers including cancer. The purpose this study to explore significance anti-COPT1 autoantibodies clinical non-small cell (NSCLC). Methods expression level COPT1 NSCLC and normal tissues was analyzed based on TCGA Human Protein Atlas (HPA) database. Through enzyme-linked immunosorbent assay (ELISA), levels samples from controls (NC), patients with benign pulmonary nodules (BPN), were detected discovery (89 NC 89 NSCLC) verification (321 NC, 321 BPN groups. ELISA results verified by western blotting indirect immunofluorescence experiments. Results Based HPA databases, mRNA protein higher than tissues. anti-COPT1-IgG anti-COPT1-IgM significantly ( P <0.05). Anti-COPT1-IgG could discriminate area under curve (AUC) values 0.733 (95% CI: 0.694-0.771) 0.679 0.638-0.720), respectively. Additionally, combination anti-COPT1-IgG, anti-COPT1-IgM, carcinoembryonic antigen (CEA) enhance efficacy increased AUC values. Conclusions Our indicated potential novel detection NSCLC. Furthermore, improved diagnostic value.

Язык: Английский

Процитировано

0